Because the agency said the main trial's data are not reliable. In a statement dated Nov. 20, 2026, the Food and Drug Administration said it issued a complete response letter to Capricor Therapeutics for its biologics license application for deramiocel, an allogeneic cardiosphere-derived cell therapy being developed to treat Duchenne muscular dystrophy. FDA said a letter from the Office of Therapeutic Products at CBER "identifies serious data integrity violations in the conduct of Study HOPE-3 that cannot be remediated post-hoc."

The agency said career scientists reviewed the original submission, inspection findings, discussion at a July 29, 2026, meeting of the Cellular, Tissue, and Gene Therapy Advisory Committee, and additional data in a later major amendment, "and determined that the current evidence submitted for deramiocel does not meet the evidentiary standard required for approval." After that advisory meeting, Capricor submitted 24-month open-label extension findings from Study HOPE-3-OLE and changed its proposed indication from treatment of cardiomyopathy in DMD to treatment of upper limb impairment. FDA said it considered that supplemental evidence and still found the standard unmet.

Among the deficiencies, FDA said serious clinical-trial data-integrity problems in HOPE-3 "render the study data unreliable and incapable of post hoc remediation." A Bioresearch Monitoring Program inspection of Capricor identified serious deficiencies in how the study was conducted. Those issues, the agency said, amplified concerns that HOPE-3 failed to meet its pre-specified primary and secondary efficacy endpoints. Even if questions of clinical meaningfulness could theoretically be addressed, "the underlying data cannot serve as a reliable foundation for a marketing approval determination." The serious deficiencies listed include unauthorized post hoc changes to the statistical analysis plan, violations of study blinding procedures, and additional protocol violations that, "individually and collectively, compromise the reliability of the study data."

FDA also issued a Regulatory Responsibility Letter, dated Nov. 20, 2026, related to the inspection observations, and said Capricor will have the opportunity to address those issues. The statement emphasizes that the agency is "deeply committed" to rare-disease treatments, points to a Rare Disease Framework Initiative launched in October 2026, and says flexibility "cannot come at the cost of the foundational requirement that the data underlying an approval decision be reliable." The July advisory meeting included public comment from people and families affected by DMD, which FDA said it considered.

This is a complete-response decision as described by FDA, not a permanent ban on all future deramiocel applications and not an approval with restrictions. The agency said it will keep working with sponsors developing treatments for DMD and other rare diseases. Families looking for a new approved DMD therapy did not get one on Nov. 20, and the official reason is the integrity and sufficiency of the evidence, as FDA laid it out in this statement.